FY2025 EPS Forecast for Gilead Sciences Raised by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of Gilead Sciences in a research note issued on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of $7.98 per share for the year, up from their prior forecast of $7.24. Cantor Fitzgerald currently has a “Neutral” rating and a $80.00 target price on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.94 per share.

Several other research analysts also recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a report on Tuesday. Bank of America reaffirmed a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Finally, Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Trading Up 2.2 %

Shares of Gilead Sciences stock opened at $110.03 on Friday. The company has a market capitalization of $137.13 billion, a P/E ratio of 297.38, a P/E/G ratio of 0.90 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a fifty day moving average of $95.05 and a 200 day moving average of $88.38. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $110.11.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 832.43%.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 713,000 shares of company stock worth $67,945,181. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently added to or reduced their stakes in the stock. Forum Financial Management LP lifted its position in shares of Gilead Sciences by 26.1% in the 4th quarter. Forum Financial Management LP now owns 23,525 shares of the biopharmaceutical company’s stock worth $2,173,000 after purchasing an additional 4,867 shares during the period. Griffith & Werner Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $1,333,000. Peak Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $837,000. Ball & Co Wealth Management Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $677,000. Finally, Toronto Dominion Bank lifted its position in shares of Gilead Sciences by 11.0% in the 4th quarter. Toronto Dominion Bank now owns 710,523 shares of the biopharmaceutical company’s stock worth $65,631,000 after purchasing an additional 70,551 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.